Naringenin decreases total cell viability. by Lauren A. Eanes (20995499)

PAP I point mutations lead to a decrease in pYV PCN, plasmid stability, and T3SS activity. by Katherine Schubert (5452712)

The introduction of mutualisms into assembled communities increases their connectance and complexity while decreasing their richness. by Gui Araujo (22170819)

“…Parameter values: interaction strengths were drawn from a half-normal distribution of zero mean and a standard deviation of 0.2, and strength for consumers was made no larger than the strength for resources. …”

Knock-down of DYRK1A decreases HBV RNAs levels in HBV-infected dHepaRG cells. by Florentin Pastor (19852287)

Table 1_Subjective spatial orientation discomfort is associated with decreased real-world spatial performance and lower cognitive function.docx by Johannes Gerb (10287758)

Mean amplitude values during a complete 360° rotation for the iliocostalis muscle. by Christoph Anders (4068499)

Mean amplitude values during a complete 360° rotation for the longissimus muscle. by Christoph Anders (4068499)

Mean amplitude values during a complete 360° rotation for the multifidus muscle. by Christoph Anders (4068499)

Cephalometric measurement points. by Lijuan Liu (136685)

Subjects:

Mean amplitude values during a complete 360° rotation for the external oblique muscle. by Christoph Anders (4068499)

Mean amplitude values during a complete 360° rotation for the internal oblique muscle. by Christoph Anders (4068499)

Mean amplitude values during a complete 360° rotation for the rectus abdominis muscle. by Christoph Anders (4068499)

The mean and standard deviation of parameters. by Sadaf Sepasgozar Sarkhosh (20436143)

“…Additionally, one-way ANCOVA revealed a significant difference between the groups post-treatment (F(1,31) = 6.011, P = 0.020, η2 = 0.162) and one month post-treatment (F(1,31) = 4.889, P = 0.035, η2 = 0.136), with ML SI being significantly lower in the exergaming group than the balance training group at both time points. …”

Changes in AL (A) and SE (B) according to the treatment time estimation curve in patients given 0.125% atropine. by Zi-Rong Chen (9227618)

Subjects:

Table 2 - Early identification of the efficacy of 0.125% atropine treatment for children with Myopia: A prospective pilot study by Zi-Rong Chen (9227618)

Subjects:

(A) Auxiliary marking points to ensure complete and accurate seating of the prosthesis. by Long Li (6555)

Subjects:

A summary of the included study characteristics. by Zahra Tajik (20752452)

“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”

Study selection criteria. by Filip Stanicic (17808254)

“…Durability was observed in a long-term follow-up trial (mean duration, 45.4 months) with a 0.9-point CAPS decrease from post-treatment.…”

PICOS criteria for the SLR. by Filip Stanicic (17808254)

“…Durability was observed in a long-term follow-up trial (mean duration, 45.4 months) with a 0.9-point CAPS decrease from post-treatment.…”

PRISMA flow chart. by Filip Stanicic (17808254)

“…Durability was observed in a long-term follow-up trial (mean duration, 45.4 months) with a 0.9-point CAPS decrease from post-treatment.…”